Privium Fund Management B.V portfolio
Concentrated managerType not verifiedPortfolio as of Sep 30, 2026 (Q3 2026) · filed with the SEC on Nov 3, 2026 · data updated on Nov 5, 2026 · Q3 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Privium Fund Management B.V reported a $516M portfolio of 58 positions to the SEC as of the end of Q3 2026. Its largest positions are TSLA, SHOP, AMD. During the quarter it opened Nebius Group and BridgeBio Pharma and exited AST Spacemobile and Vertex Pharmaceuticals.
Sections with a free account
What changed this quarter
54 positions with a change (9 new, 21 added to, 12 trimmed, 12 sold). 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Space Exploration Technologies+525%more sharesIncreased1.3% → 7.3%
- AST Spacemobile−2.4 ppof portfolioSold out2.4% → —
- Spotify Technology−40%fewer sharesReduced4.6% → 3.1%
- Shopify−18%fewer sharesReduced7.8% → 8.8%
- Nebius Group+1.7 ppof portfolioNew— → 1.8%
- Cerebras Systems+83%more sharesIncreased2.5% → 3.8%
- BridgeBio Pharma+1.1 ppof portfolioNew— → 1.1%
- Vertex Pharmaceuticals−0.9 ppof portfolioSold out0.9% → —
- UroGen Pharma−49%fewer sharesReduced1.4% → 0.9%
- Neurocrine Biosciences+0.7 ppof portfolioNew— → 0.7%
- Viridian Therapeutics−0.6 ppof portfolioSold out0.6% → —
- Opendoor Technologies+30%more sharesIncreased3.3% → 2.4%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- TeslaTSLA15.5%
- ShopifySHOP8.8%
- Advanced Micro DevicesAMD7.4%
- Space Exploration TechnologiesSPCX7.3%
- Palantir TechnologiesPLTR7.3%
- Amazon.comAMZN6.8%
- Cerebras SystemsCBRS3.8%
- NVIDIANVDA3.6%
- Spotify TechnologySPOT3.1%
- Ionis PharmaceuticalsIONS3.0%
- IRENIREN2.9%
- Arrowhead PharmaceuticalsARWR2.7%
- LemonadeLMND2.4%
- Opendoor TechnologiesOPEN2.4%
- BiogenBIIB2.1%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Information Technology 36%
- ● Health Care 25%
- ● Consumer Discretionary 22%
- ● Industrials 7%
- ● Communication Services 3%
- ● Financials 2%
- ● Real Estate 2%
- ● Consumer Staples 1%
- ● Energy 1%
How its portfolio changed (8 quarters)
Q3 2026: 58
Q3 2026: 67%
Q3 2026: 12.9%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Type not verified. It meets the portfolio criteria of a concentrated manager, but its type is not verified: we found no official document that is enough to say what kind of entity it is. It may be an investment firm, but also an adviser adding up client accounts, a bank or a family vehicle. It counts in the tallies like the rest; keep that in mind when reading it. How the type is assigned
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- Simcoe Capital ManagementInvestment firm · $515M
- Palo Duro Investment PartnersInvestment firm · $518M
- Gagnon Securities$519M
- Medina Value PartnersInvestment firm · $510M
- Stieven Capital AdvisorsInvestment firm · $524M
- DAFNA Capital ManagementInvestment firm · $524M